Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Equillium, Inc. - Common Stock
(NQ:
EQ
)
1.452
+0.042 (+2.99%)
Delayed Quote
Updated: 11:43 AM EDT, Oct 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Equillium, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2025
From
Equillium, Inc.
Via
Business Wire
Equillium to Participate in the Cantor Global Healthcare Conference 2025
August 29, 2025
From
Equillium, Inc.
Via
Business Wire
Wall Street Eyes: EQ, PRSO, WLGS, ENTO, GIBO Stocks Lead Sub-$1 Surge
August 11, 2025
Via
AB Newswire
Topics
Artificial Intelligence
Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic
August 11, 2025
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy
August 04, 2025
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists
May 06, 2025
From
Equillium, Inc.
Via
Business Wire
Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504
May 01, 2025
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Feedback from the U.S. Food and Drug Administration
April 24, 2025
From
Equillium, Inc.
Via
Business Wire
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights
March 27, 2025
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease
March 27, 2025
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
February 06, 2025
From
Equillium, Inc.
Via
Business Wire
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
November 13, 2024
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the Stifel Healthcare Conference
November 13, 2024
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer
November 12, 2024
From
Equillium Inc.
Via
Business Wire
Equillium Maintains Rights to Itolizumab Following Ono Partnership
October 31, 2024
From
Equillium Inc.
Via
Business Wire
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
October 07, 2024
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit
September 10, 2024
From
Equillium, Inc.
Via
Business Wire
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2024
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
August 28, 2024
From
Equillium, Inc.
Via
Business Wire
Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights
August 08, 2024
From
Equillium Inc.
Via
Business Wire
Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
August 06, 2024
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
July 18, 2024
From
Equillium, Inc.
Via
Business Wire
Equillium to Participate in Upcoming Investor Conferences
July 02, 2024
From
Equillium, Inc.
Via
Business Wire
Equillium to be included in the Russell Microcap® Index
June 12, 2024
From
Equillium, Inc.
Via
Business Wire
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2024
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata
June 04, 2024
From
Equillium Inc.
Via
Business Wire
Equillium to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
May 14, 2024
From
Equillium, Inc.
Via
Business Wire
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
May 09, 2024
From
Equillium Inc.
Via
Business Wire
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
May 07, 2024
From
Equillium, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
